- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 26, Issue 18, 2019
Current Medicinal Chemistry - Volume 26, Issue 18, 2019
Volume 26, Issue 18, 2019
-
-
Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
More LessMatrix metalloproteinases (MMPs) play a key role in remodeling of the extracellular matrix (ECM) and, at the same time, influence cell differentiation, migration, proliferation, and survival. Their importance in a variety of human diseases including cancer, rheumatoid arthritis, pulmonary emphysema and fibrotic disorders has been known for many years but special attention should be paid on the role of MMPs i Read More
-
-
-
Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Inflammation plays a crucial role in the development of many complex diseases and disorders including autoimmune diseases, metabolic syndrome, neurodegenerative diseases, and cardiovascular pathologies. Prostaglandins play a regulatory role in inflammation. Cyclooxygenases are the main mediators of inflammation by catalyzing the initial step of arachidonic acid metabolism and prostaglandin synthesis. The di Read More
-
-
-
Lactate Dehydrogenase Inhibition: Biochemical Relevance and Therapeutical Potential
Authors: Giuseppina Laganà, Davide Barreca, Antonella Calderaro and Ersilia BelloccoLactate dehydrogenase (LHD) is a key enzyme of anaerobic metabolism in almost all living organisms and it is also a functional checkpoint for glucose restoration during gluconeogenesis and single-stranded DNA metabolism. This enzyme has a well preserved structure during evolution and among the species, with little, but sometimes very useful, changes in the amino acid sequence, which makes it an attractive target for t Read More
-
-
-
Aporphines and Alzheimer’s Disease: Towards a Medical Approach Facing the Future
Authors: Seyed M. Nabavi, Eugenio Uriarte, Luca Rastrelli and Eduardo Sobarzo-SánchezAlzheimer's disease (AD) is a neurodegenerative disease that reduces progressively the part cognitive inside the Central Nervous System (CNS) and that affects the memories and emotions of the patients who endure this disease. Many drugs have been assessed in patients with different evolutionary grades of the disease, having diverse results, depending on the used compound. Some of them afford dependence and ma Read More
-
-
-
Benzimidazole-derived Compounds Designed for Different Targets of Alzheimer’s Disease
More LessBenzimidazole scaffold has been efficiently used for the design of various pharmacologically active molecules. Indeed, there are various benzimidazole drugs, available today, employed for the treatment of different diseases. Although there is no benzimidazole moiety containing a drug used in clinic today for the treatment of Alzheimer’s Disease (AD), there have been many benzimidazole derivative compounds des Read More
-
-
-
Advances in the Tyrosinase Inhibitors from Plant Source
Authors: Marco Bonesi, Jianbo Xiao, Rosa Tundis, Francesca Aiello, Vincenzo Sicari and Monica R. LoizzoTyrosinase is a multifunctional copper-containing oxidase which catalyses the oxidation of tyrosine to produce melanin. The alteration in melanin biosynthesis occurs in many diseases. The pigment has a protecting role against skin photo-carcinogenesis, but anomalous melanin pigmentation is an aesthetic problem in human beings. Moreover, the formation of neuromelanin in human brain could contribute to the neurodegenera Read More
-
-
-
Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Authors: Juan A. Páez and Nuria E. CampilloThe discovery of cannabinoid receptors at the beginning of the 1990s, CB1 cloned in 1990 and CB2 cloned in 1993, and the availability of selective and potent cannabimimetics could only be justified by the existence of endogenous ligands that are capable of binding to them. Thus, the characterisation and cloning of the first cannabinoid receptor (CB1) led to the isolation and characterisation of the first endocannabinoid Read More
-
-
-
Metal–Organic Framework (MOF)-based Nanomaterials for Biomedical Applications
Authors: Zhidong Luo, Shuran Fan, Chuying Gu, Weicong Liu, Jinxiang Chen, Baohong Li and Jianqiang LiuBackground: Metal-organic frameworks (MOFs), as a new class of porous organic-inorganic crystalline hybrid materials that governed by the self-assembled of metal atoms and organic struts have attracted tremendous attention because of their special properties. Recently, some more documents have reported different types of nanoscale metal-organic frameworks (NMOFs) as biodegradable and physiological pH-respo Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
- Issue 42
- Issue 41
- Issue 40
- Issue 39
- Issue 38
- Issue 37
- Issue 36
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
